It ranges from 9.1% in the STING study up to 27% in a retrospective study by Richter-Schrag et al., but it has to be noted that the latter is hardly comparable to our study as it included various indications of OTSC therapy (e.g. bleeding anastomotic ulcers and malignancies) [11, 12]. This evidence concerns the gene STING1 and cancer.